Effect of Optimization of Glycaemic Control on Mannan-Binding Lectin in Type 1 Diabetes
Objective. Mannan-binding lectin (MBL) concentration in plasma is increased in subjects with type 1 diabetes and associated with increased mortality and risk of diabetic nephropathy. Recent findings show that pancreas transplantation reduces MBL concentration. Whether the increased MBL concentration...
Saved in:
Main Authors: | , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2017-01-01
|
Series: | Journal of Diabetes Research |
Online Access: | http://dx.doi.org/10.1155/2017/1249729 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
_version_ | 1832564957535797248 |
---|---|
author | Gry Høst Dørflinger Charlotte Brink Holt Steffen Thiel Jakob Appel Østergaard Troels Krarup Hansen |
author_facet | Gry Høst Dørflinger Charlotte Brink Holt Steffen Thiel Jakob Appel Østergaard Troels Krarup Hansen |
author_sort | Gry Høst Dørflinger |
collection | DOAJ |
description | Objective. Mannan-binding lectin (MBL) concentration in plasma is increased in subjects with type 1 diabetes and associated with increased mortality and risk of diabetic nephropathy. Recent findings show that pancreas transplantation reduces MBL concentration. Whether the increased MBL concentration is reversed by improved glycaemic control remains unknown. We investigated the effects of improved glycaemic control on MBL concentration in patients with type 1 diabetes. Methods. We measured MBL, fructosamine, and HbA1cat baseline and after 6 weeks in 52 type 1 diabetic patients following the change from conventional insulin therapy to insulin pump therapy. Results. After initiation of insulin pump therapy, the total daily insulin dose was significantly reduced (from 51 ± 18 IE/day to 39 ± 13 IE/day, P<0.0001). There was a significant decrease in HbA1c from 8.6% to 7.7% (from 70 mmol/mol to 61 mmol/mol, P<0.0001) and in fructosamine levels (from 356 μmol/L to 311 μmol/L, P<0.0001). MBL levels decreased by 10% from 2165 μg/L (IQR 919–3389 μg/L) at baseline to 1928 μ/L (IQR 811–2758 μg/L) at follow-up (P=0.005), but MBL change was not significantly correlated with changes in insulin dose, HbA1c, or fructosamine. Conclusions. MBL concentration decreased following the initiation of insulin pump therapy in patients with type 1 diabetes and did not correlate with changes in glycaemic control. |
format | Article |
id | doaj-art-5ccb89bfec2041939473807ec2eb7a36 |
institution | Kabale University |
issn | 2314-6745 2314-6753 |
language | English |
publishDate | 2017-01-01 |
publisher | Wiley |
record_format | Article |
series | Journal of Diabetes Research |
spelling | doaj-art-5ccb89bfec2041939473807ec2eb7a362025-02-03T01:09:48ZengWileyJournal of Diabetes Research2314-67452314-67532017-01-01201710.1155/2017/12497291249729Effect of Optimization of Glycaemic Control on Mannan-Binding Lectin in Type 1 DiabetesGry Høst Dørflinger0Charlotte Brink Holt1Steffen Thiel2Jakob Appel Østergaard3Troels Krarup Hansen4Department of Endocrinology and Internal Medicine, Aarhus University Hospital, 8000 Aarhus, DenmarkDepartment of Endocrinology and Internal Medicine, Aarhus University Hospital, 8000 Aarhus, DenmarkDepartment of Biomedicine, Aarhus University, 8000 Aarhus, DenmarkDepartment of Endocrinology and Internal Medicine, Aarhus University Hospital, 8000 Aarhus, DenmarkDepartment of Endocrinology and Internal Medicine, Aarhus University Hospital, 8000 Aarhus, DenmarkObjective. Mannan-binding lectin (MBL) concentration in plasma is increased in subjects with type 1 diabetes and associated with increased mortality and risk of diabetic nephropathy. Recent findings show that pancreas transplantation reduces MBL concentration. Whether the increased MBL concentration is reversed by improved glycaemic control remains unknown. We investigated the effects of improved glycaemic control on MBL concentration in patients with type 1 diabetes. Methods. We measured MBL, fructosamine, and HbA1cat baseline and after 6 weeks in 52 type 1 diabetic patients following the change from conventional insulin therapy to insulin pump therapy. Results. After initiation of insulin pump therapy, the total daily insulin dose was significantly reduced (from 51 ± 18 IE/day to 39 ± 13 IE/day, P<0.0001). There was a significant decrease in HbA1c from 8.6% to 7.7% (from 70 mmol/mol to 61 mmol/mol, P<0.0001) and in fructosamine levels (from 356 μmol/L to 311 μmol/L, P<0.0001). MBL levels decreased by 10% from 2165 μg/L (IQR 919–3389 μg/L) at baseline to 1928 μ/L (IQR 811–2758 μg/L) at follow-up (P=0.005), but MBL change was not significantly correlated with changes in insulin dose, HbA1c, or fructosamine. Conclusions. MBL concentration decreased following the initiation of insulin pump therapy in patients with type 1 diabetes and did not correlate with changes in glycaemic control.http://dx.doi.org/10.1155/2017/1249729 |
spellingShingle | Gry Høst Dørflinger Charlotte Brink Holt Steffen Thiel Jakob Appel Østergaard Troels Krarup Hansen Effect of Optimization of Glycaemic Control on Mannan-Binding Lectin in Type 1 Diabetes Journal of Diabetes Research |
title | Effect of Optimization of Glycaemic Control on Mannan-Binding Lectin in Type 1 Diabetes |
title_full | Effect of Optimization of Glycaemic Control on Mannan-Binding Lectin in Type 1 Diabetes |
title_fullStr | Effect of Optimization of Glycaemic Control on Mannan-Binding Lectin in Type 1 Diabetes |
title_full_unstemmed | Effect of Optimization of Glycaemic Control on Mannan-Binding Lectin in Type 1 Diabetes |
title_short | Effect of Optimization of Glycaemic Control on Mannan-Binding Lectin in Type 1 Diabetes |
title_sort | effect of optimization of glycaemic control on mannan binding lectin in type 1 diabetes |
url | http://dx.doi.org/10.1155/2017/1249729 |
work_keys_str_mv | AT gryhøstdørflinger effectofoptimizationofglycaemiccontrolonmannanbindinglectinintype1diabetes AT charlottebrinkholt effectofoptimizationofglycaemiccontrolonmannanbindinglectinintype1diabetes AT steffenthiel effectofoptimizationofglycaemiccontrolonmannanbindinglectinintype1diabetes AT jakobappeløstergaard effectofoptimizationofglycaemiccontrolonmannanbindinglectinintype1diabetes AT troelskraruphansen effectofoptimizationofglycaemiccontrolonmannanbindinglectinintype1diabetes |